Coordinatore | THE UNIVERSITY OF WARWICK
Organization address
address: Kirby Corner Road - University House - contact info |
Nazionalità Coordinatore | United Kingdom [UK] |
Totale costo | 7˙746˙214 € |
EC contributo | 6˙000˙000 € |
Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
Code Call | FP7-HEALTH-2013-INNOVATION-1 |
Funding Scheme | CP-FP |
Anno di inizio | 2014 |
Periodo (anno-mese-giorno) | 2014-02-01 - 2019-01-31 |
# | ||||
---|---|---|---|---|
1 |
THE UNIVERSITY OF WARWICK
Organization address
address: Kirby Corner Road - University House - contact info |
UK (COVENTRY) | coordinator | 1˙733˙100.00 |
2 |
CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER
Organization address
address: Avenue du Doyen Gaston Giraud 191 contact info |
FR (MONTPELLIER) | participant | 512˙200.00 |
3 |
KING'S COLLEGE LONDON
Organization address
address: Strand contact info |
UK (LONDON) | participant | 511˙200.00 |
4 |
UNIVERSITAET ULM
Organization address
address: HELMHOLTZSTRASSE 16 contact info |
DE (ULM) | participant | 511˙200.00 |
5 |
KATHOLIEKE UNIVERSITEIT LEUVEN
Organization address
address: Oude Markt 13 contact info |
BE (LEUVEN) | participant | 446˙000.00 |
6 |
PROVINCIA LOMBARDO VENETA ORDINE OSPEDALIERO DI SAN GIOVANNI DI DIO - FATEBENEFRATELLI
Organization address
address: Via San Vittore 12 contact info |
IT (MILANO) | participant | 402˙500.00 |
7 |
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN
Organization address
address: BELFIELD contact info |
IE (DUBLIN) | participant | 367˙000.00 |
8 | Concentris Research Management GmbH | DE | participant | 360˙000.00 |
9 |
STICHTING YULIUS
Organization address
address: HELLINGEN 21 contact info |
NL (DORDRECHT) | participant | 360˙000.00 |
10 |
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Organization address
address: 's Gravendijkwal 230 contact info |
NL (ROTTERDAM) | participant | 322˙000.00 |
11 |
KLINICKI BOLNICKI CENTAR SPLIT
Organization address
address: SPINCICEVA 1 contact info |
HR (SPLIT) | participant | 250˙000.00 |
12 |
HEALTHTRACKER LTD
Organization address
address: Foxon Close 18 contact info |
UK (Caterham) | participant | 224˙800.00 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
'Transition to adulthood is the period of onset of most of the serious mental disorders that disable or kill in adult life. Current service configuration of distinct Child and Adolescent Mental Health (CAMHS) and Adult Mental Health (AMHS) Services is considered the weakest link where the care pathway should be most robust. Transition-related discontinuity of care is a major socioeconomic and societal challenge for the EU. The MILESTONE project is an EU-wide study determining care gaps in current services across diverse healthcare systems and robustly evaluating an innovative transitional care model. In ten high-quality work packages we will map current services and transitional policies across EU; develop and validate transition-specific outcomes measures; conduct a longitudinal cohort study of transition process and outcomes across eight EU countries; develop and test, in a cluster-randomised trial, the clinical and cost-effectiveness of an innovative transitional care model; create clinical, organisational, policy and ethics guidelines for improving care and outcomes for transition age youth; and develop and implement training packages for clinicians across EU. The project will provide robust evidence for the most cost-effective way to meet the as-yet-unmet need of young people who fall through the CAMHS-AMHS divide; facilitate the development of integrated models of care and function; improve health care outcomes and system efficiencies; and ensure take-up of best practice. The project has active and intensive participation of young people, carers, advocacy groups and key stakeholders and involves two SMEs, Concentris and HealthTracker. Findings from the project will transform mental health care in EU for young people. Our results will assist policy makers in making informed and evidence-based decisions for improving health systems, enhancing patient outcomes, quality of life, service satisfaction, and improving health status at individual and population levels.'
Evaluation of phage therapy for the treatment of Escherichia coli and Pseudomonas aeruginosa burn wound infections (Phase I-II clinical trial)
Read MoreDevelopment of very promising humanized therapeutic mAbs efficiently neutralizing a novel immunosuppressive pathway involved in a wide range of cancers
Read More